Eculizumab—a humanized recombinant monoclonal antibody—binds to C5, shows efficacy in managing refractory cases of CAPS [73], post-kidney transplant TMA [74,75], and lupus nephritis with TMA [76]. Here, C5 is linked to cryopyrin-associated periodic syndrome.